Cleerly, Inc.
Printed as of 12/19/2025

Disclosures

Personal Commercial (5)

Company Name	Relationship Category	Compensation Level	Topic Area(s)
Self			
Arineta	Consultant Fees/Honoraria	None (\$0)	General Cardiology
Cleerly	Ownership Interest/Partnership/Principal	Significant (>= \$5,000)	Noninvasive Imaging
Cleerly	Salary	Significant (>= \$5,000)	General Cardiology
Cleerly	Ownership Interest/Partnership/Principal	None (\$0)	General Cardiology
Tourmaline Bio	Consultant Fees/Honoraria	Modest (< \$5,000)	Other

Additional Personal Commercial Disclosures for Education Activities (0)

No disclosures on record

Personal Organizational or Other Non-Commercial (6)

Non-Commercial Enity Name	Relationship Category	Compensation Level	Topic Area(s)
Self			
GE Healthcare	Research/Research Grants ‡ DISCOVER-VP	Significant (>= \$5,000)	General Cardiology
NIH/NHLBI	Research/Research Grants ‡ Computerized Visualization and Prediction of Coronary Artery Ischemia	Significant (>= \$5,000)	General Cardiology
NIH/NHLBI	Research/Research Grants ‡ U01 HL 105907: The primary aim of the International Study of Comparative Health Effectiveness with Medical and Invasive Approaches, or ISCHEMIA trial	Significant (>= \$5,000)	Noninvasive Imaging
NIH/NHLBI	Research/Research Grants ‡ R01 HL118019: Anatomic and Physiologic Determinants of Vessel-Specific Ischemia by Coronary CT	Significant (>= \$5,000)	Noninvasive Imaging
NIH/NHLBI	Research/Research Grants ‡ R01 HL115150: Gender-Specific Coronary Plaque Characteristics and Risk of Myocardial Infarction	Significant (>= \$5,000)	Noninvasive Imaging
NIH/NHLBI	Research/Research Grants ‡ R01 HL111141: Dual Energy Computed Tomography for Determining Coronary Lesion- Specific Ischemia	Significant (>= \$5,000)	Noninvasive Imaging

Clinical Trial Enroller (0)

No disclosures on record

Institutional Financial Decision-Making Role (0)

No disclosures on record

Expert Witness Testimony (0)

No disclosures on record

† Commercial Funding Source | ‡ Trial Name

Agreement

Confidentiality, Disclosure and Assignment Agreement | Signed on 9/27/2024

URL for full agreement: http://disclosures.acc.org/Public/Definition/ConfidentialityDisclosureandAssignmentAgreement

Embargo | Signed on 9/27/2024

URL for full agreement: http://disclosures.acc.org/Public/Definition/EmbargoAgreement

On-Going Obligation Agreement | Signed on 9/27/2024

ACC and Disclosures

ACC is committed to ensuring balance, independence, objectivity, and scientific rigor in their governance, programmatic, educational, chapter, and other activities. Fulfilling this commitment depends on member and public confidence in the College's integrity and objectivity. The College recognizes that the activities of College members in their practice, research, and other volunteer and private endeavors could lead to the development of conflicts of interest. Therefore, the College has established a Disclosure Policy and conflict of interest management process as appropriate. All members involved in College governance, including all committees and task forces, programmatic, certified educational, chapter, and other activities must provide complete, timely, accurate, and signed disclosure statements. Compliance with this process is mandatory for participation in College activities.